Nile Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
For patients with acute decompensated heart failure, Nile Therapeutics is developing a drug related to known natriuretic peptides, which addresses three important mechanisms. CD-NP shows promise in fluid unloading, but without the side effect of low blood pressure that often accompanies other medications; it as the potential to reduce filling pressure; and it may also preserve, or possibly enhance, renal function.